A peptide dimer compound comprising two peptide monomer subunits of Formula Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14 (Formula I), or a pharmaceutically acceptable salt thereof, wherein Xaa1 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Ser, Met, Thr, a suitable isostere, and a corresponding D-amino acid; Xaa2 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Ser, Met, Thr, a suitable isostere, and a corresponding D-amino acid; Xaa3 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Met, Thr, Ser, a suitable isostere, and a corresponding D-amino acid; Xaa4 is Cys or Pen; Xaa5 is N-Me-Arg; Xaa6 is Ser; Xaa7 is Asp; Xaa8 is Thr; Xaa9 is Leu; Xaa10 is Cys or Pen; Xaa11 is absent or selected from the group consisting of: Gly, Gln, Asn, Asp, Ala, Ile, Leu, Val, Met, Thr, Lys, Trp, Tyr, His, Glu, Ser, Arg, Pro, Phe, Sar, 1-Nal, 2-Nal, HPhe, Phe(4-F), dihydro-Trp, Dap, Dab, Orn, D-Orn, D-Dap, D-Dab, Bip, Ala(3,3 diphenyl), Biphenyl-Ala, D-Phe, D-Trp, D-Tyr, D-Glu, D-His, D-Lys, 3,3-diPhe, β-HTrp, F(4-CF3), O-Me-Tyr, 4-Me-Phe, an aromatic ring substituted Phe, an aromatic ring substituted Trp, an aromatic ring substituted His, a hetero aromatic amino acid, N-Me-Lys, N-Me-Lys(Ac), 4-Me-Phe, a corresponding D-amino acid; a suitable isostere; and a suitable linker moiety. Xaa12 is selected from the group consisting of: Glu, β-HGlu, 2-Nal, 1-Nal, D-Asp, Bip, β-HPhe, βGlu, a suitable isostere, a suitable linker moiety, and a corresponding D-amino acid; Xaa13 is absent or selected from the group consisting of: Gln, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Leu, Val, Tyr, Trp, Met, Glu, Gla, Ser, Asn, Dap, Dab, Orn, D-Orn, N-Me-Orn, N-Me-Dap, N-Me-Dab, N-Me-Lys, D-Dap, D-Dab, D-Lys, N-Me-D-Lys, a suitable isostere, and a corresponding D-amino acid; and Xaa14 is absent or selected from the group consisting of: a natural amino acid, a suitable isostere, and a corresponding D-amino acid, wherein the peptide dimer compound comprises a disulfide bond between Xaa4 and Xaa10, and wherein the two peptide monomer subunits are joined by a suitable linker moiety, optionally wherein the N-terminus of each monomer subunit is joined by the suitable linker moiety to provide an N-terminus dimer compound, or optionally wherein the C-terminus of each monomer subunit is joined by the suitable linker moiety to provide a C-terminus dimer compound. Xaa1 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Ser, Met, Thr, a suitable isostere, and a corresponding D-amino acid; Xaa2 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Ser, Met, Thr, a suitable isostere, and a corresponding D-amino acid; Xaa3 is absent or selected from the group consisting of: Gln, Asp, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Asn, Glu, Leu, Val, Tyr, Trp, Met, Thr, Ser, a suitable isostere, and a corresponding D-amino acid; Xaa4 is Cys or Pen; Xaa5 is N-Me-Arg; Xaa6 is Ser; Xaa7 is Asp; Xaa8 is Thr; Xaa9 is Leu; Xaa10 is Cys or Pen; Xaa11 is absent or selected from the group consisting of: Gly, Gln, Asn, Asp, Ala, Ile, Leu, Val, Met, Thr, Lys, Trp, Tyr, His, Glu, Ser, Arg, Pro, Phe, Sar, 1-Nal, 2-Nal, HPhe, Phe(4-F), dihydro-Trp, Dap, Dab, Orn, D-Orn, D-Dap, D-Dab, Bip, Ala(3,3 diphenyl), Biphenyl-Ala, D-Phe, D-Trp, D-Tyr, D-Glu, D-His, D-Lys, 3,3-diPhe, β-HTrp, F(4-CF3), O-Me-Tyr, 4-Me-Phe, an aromatic ring substituted Phe, an aromatic ring substituted Trp, an aromatic ring substituted His, a hetero aromatic amino acid, N-Me-Lys, N-Me-Lys(Ac), 4-Me-Phe, a corresponding D-amino acid; a suitable isostere; and a suitable linker moiety. Xaa12 is selected from the group consisting of: Glu, β-HGlu, 2-Nal, 1-Nal, D-Asp, Bip, β-HPhe, βGlu, a suitable isostere, a suitable linker moiety, and a corresponding D-amino acid; Xaa13 is absent or selected from the group consisting of: Gln, Pro, Gly, His, Ala, Ile, Phe, Lys, Arg, Leu, Val, Tyr, Trp, Met, Glu, Gla, Ser, Asn, Dap, Dab, Orn, D-Orn, N-Me-Orn, N-Me-Dap, N-Me-Dab, N-Me-Lys, D-Dap, D-Dab, D-Lys, N-Me-D-Lys, a suitable isostere, and a corresponding D-amino acid; and Xaa14 is absent or selected from the group consisting of: a natural amino acid, a suitable isostere, and a corresponding D-amino acid,